Companies ZimVie Inc.
ZimVie (ZIMV): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me ZimVie Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers32nd pct.Of 22 peer CEOs
CEO pay ratio81:1To the median employee
CEO pay, last three years
- $10,411,213FY2022
- $4,226,944FY2023
- $7,209,869FY2024
CEO total pay was $7,209,869 in fiscal 2024, up from $4,226,944 in fiscal 2023.
FY2024: salary $818,461 · bonus $0 · stock awards $6,367,343 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at ZimVie Inc. in fiscal 2024?
As disclosed, Vafa Jamali (President and Chief Executive Officer) was the highest-paid executive at ZimVie Inc. in fiscal 2024, with total compensation of $7,209,869.
How does ZimVie Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Vafa Jamali's total compensation ranked at the 32nd percentile of ZimVie Inc.'s disclosed peer group.
What is ZimVie Inc.'s CEO-to-median employee pay ratio?
As disclosed, ZimVie Inc.'s CEO-to-median employee pay ratio was 81:1.
How did shareholders vote on ZimVie Inc.'s executive compensation?
As disclosed, 54.67% of shareholders supported ZimVie Inc.'s executive compensation in the latest say-on-pay vote.
How much does ZimVie Inc. spend in total on board compensation for fiscal 2024?
As disclosed, ZimVie Inc. reported total board compensation of $1,542,000 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Vafa Jamali | $818,461 | $0 | $6,367,343 | $0 | $0 | $0 | $24,065 | $7,209,869 |
| President and Chief Executive Officer | ||||||||
| Richard Heppenstall | 475,477 | 0 | 1,839,114 | 0 | 0 | 0 | 24,512 | 2,339,103 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| Heather Kidwell | 451,169 | 0 | 1,069,565 | 0 | 0 | 0 | 23,458 | 1,544,283 |
| Senior Vice President, Chief Legal, Compliance and Human Resources Officer and Corporate Secretary | ||||||||
| Indraneel Kanaglekar | 391,004 | 0 | 966,597 | 0 | 0 | 0 | 23,093 | 1,380,548 |
| Senior Vice President, Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Vafa Jamali | $7,209,869 | $4,226,944 | $10,411,213 | ↑ +2,982,925 |
| Richard Heppenstall | 2,339,103 | 1,665,386 | 2,749,858 | ↑ +673,717 |
| Heather Kidwell | 1,544,283 | 1,068,543 | 1,304,548 | ↑ +475,740 |
| Indraneel Kanaglekar | 1,380,548 | 1,139,738 | 1,734,539 | ↑ +240,810 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, retain, and motivate a highly qualified senior leadership team, focus executives on specific financial, operational, and strategic objectives, and create a direct relationship between pay and performance. The committee targets total direct compensation at market-competitive levels while placing a greater emphasis on at-risk equity-based compensation to align executives' interests with long-term shareholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Richard Heppenstall | RSU | 2024-03-07 | — | — | 73,948 | — | $1,300,000 |
| Vafa Jamali | RSU | 2024-03-07 | — | — | 270,193 | — | 4,750,000 |
| Heather Kidwell | RSU | 2024-03-07 | — | — | 45,506 | — | 800,000 |
| Richard Heppenstall | Conversion | 2024-09-11 | — | — | — | — | 539,114 |
| Heather Kidwell | Conversion | 2024-09-11 | — | — | — | — | 269,565 |
| Indraneel Kanaglekar | Conversion | 2024-09-11 | — | — | — | — | 366,597 |
| Vafa Jamali | Conversion | 2024-09-11 | — | — | — | — | 1,617,343 |
| Indraneel Kanaglekar | RSU | 2024-03-07 | — | — | 34,130 | — | 600,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Richard Heppenstall | $1,300,000 | $0 | $0 | 0.0% |
| Vafa Jamali | 4,750,000 | 0 | 0 | 0.0% |
| Heather Kidwell | 800,000 | 0 | 0 | 0.0% |
| Indraneel Kanaglekar | 600,000 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Indraneel Kanaglekar | RSU | 592 | — | $8,258 |
| Indraneel Kanaglekar | Option | 2,348 | 31.9 | — |
| Heather Kidwell | Option | 2,367 | 32.26 | — |
| Indraneel Kanaglekar | Option | 2,611 | 32.26 | — |
| Heather Kidwell | RSU | 2,775 | — | 38,711 |
| Indraneel Kanaglekar | RSU | 4,163 | — | 58,074 |
| Richard Heppenstall | RSU | 4,340 | — | 60,543 |
| Heather Kidwell | Option | 5,460 | 24.02 | — |
| Richard Heppenstall | RSU | 6,938 | — | 96,785 |
| Indraneel Kanaglekar | Option | 8,190 | 24.02 | — |
| Richard Heppenstall | Option | 13,650 | 24.02 | — |
| Vafa Jamali | RSU | 13,694 | — | 191,031 |
| Heather Kidwell | RSU | 16,126 | — | 224,958 |
| Richard Heppenstall | Option | 16,412 | 29.26 | — |
| Vafa Jamali | RSU | 20,815 | — | 290,369 |
| Vafa Jamali | RSU | 21,331 | — | 297,567 |
| Indraneel Kanaglekar | RSU | 21,931 | — | 305,937 |
| Heather Kidwell | RSU | 24,190 | — | 337,451 |
| Richard Heppenstall | RSU | 32,253 | — | 449,929 |
| Indraneel Kanaglekar | RSU | 32,898 | — | 458,927 |
| Indraneel Kanaglekar | RSU | 34,130 | — | 476,114 |
| Vafa Jamali | Option | 40,950 | 24.02 | — |
| Vafa Jamali | Option | 41,220 | 23.44 | — |
| Vafa Jamali | Option | 43,049 | 32.26 | — |
| Heather Kidwell | RSU | 45,507 | — | 634,823 |
| Richard Heppenstall | RSU | 48,380 | — | 674,901 |
| Vafa Jamali | Option | 50,068 | 32.42 | — |
| Richard Heppenstall | RSU | 73,948 | — | 1,031,575 |
| Vafa Jamali | RSU | 96,758 | — | 1,349,774 |
| Vafa Jamali | RSU | 145,138 | — | 2,024,675 |
| Vafa Jamali | RSU | 270,194 | — | 3,769,206 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David KingIndependent · Board Chair · Audit Committee · Compensation Committee · Corporate Governance Committee (Chair) · Quality, Regulatory and Technology Committee · Not standing for re-election | $160,000 | $258,400 | — | — | — | $418,400 |
| Karen MatusinecIndependent · Audit Committee (Chair) · Compensation Committee · Corporate Governance Committee · Quality, Regulatory and Technology Committee | 95,000 | 193,400 | — | — | — | 288,400 |
| Richard Kuntz, M.D., M.ScIndependent · Audit Committee · Compensation Committee · Corporate Governance Committee · Quality, Regulatory and Technology Committee | 85,000 | 193,400 | — | — | — | 278,400 |
| Sally CrawfordIndependent · Audit Committee · Compensation Committee (Chair) · Corporate Governance Committee · Quality, Regulatory and Technology Committee | 85,000 | 193,400 | — | — | — | 278,400 |
| Vinit AsarIndependent · Lead Independent Director · Audit Committee · Compensation Committee · Corporate Governance Committee · Quality, Regulatory and Technology Committee (Chair) | 85,000 | 193,400 | — | — | — | 278,400 |
| Vafa JamaliEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $70,000 |
|---|---|
| Annual equity retainer | $185,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 15,000 / 15,000 |
| Stock ownership guideline | $5,000 |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $510,000 |
| Equity awards (grant-date value) | $1,032,000 |
| All other compensation | $0 |
| Total cost of the board | $1,542,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ZimVie as a peer
Companies that benchmark against ZIMV
4 companies name ZIMV as a compensation peer
- Inogen IncINGNFY2025
- Organogenesis Holdings Inc.ORGOFY2025
- Orthofix Medical Inc.OFIXFY2025
- Varex Imaging CorpVREXFY2025
Each company listed discloses ZIMV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ZIMV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ATRC AtriCure, Inc.CNMD CONMED CorporationICUI ICU Medical, Inc.HAE Haemonetics CorporationATEC Alphatec Holdings, Inc.OFIX Orthofix Medical Inc.MMSI Merit Medical Systems, Inc.NVST Envista Holdings CorporationAVNS Avanos Medical, Inc.BVS Bioventus Inc.EMBC Embecta Corp.GMED Globus Medical, Inc.INGN Inogen, Inc.ITGR Integer Holdings CorporationIART Integra LifeSciences Holdings CorporationLIVN LivaNova PLCVREX Varex Imaging CorporationGKOS Glaukos CorporationAORT Artivion, Inc.NVRO Nevro Corp.FNA Paragon 28, Inc.NUVA NuVasive, Inc.
Peer reciprocity
The companies ZimVie Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Merit Medical Systems, Inc. | 2025 | Fred Lampropoulos | $1,890,000 | $9,313,606 | $0 | $1,882,894 | $13,755,143 |
| 2 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 3 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 4 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 5 | Envista Holdings Corporation | 2025 | Paul Keel | 1,100,000 | 5,440,152 | 1,360,045 | 2,486,550 | 10,559,567 |
| 6 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 7 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 8 | Embecta Corp. | 2025 | Devdatt Kurdikar | 976,923 | 7,000,008 | 0 | 1,399,540 | 9,400,088 |
| 9 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 10 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 11 | Integer Holdings Corporation | 2025 | Joseph Dziedzic | 1,235,000 | 5,999,951 | 0 | 1,323,766 | 8,671,332 |
| 12 | NuVasive, Inc. | 2022 | J. Christopher Barry | 896,635 | 5,000,093 | 0 | 2,157,750 | 8,077,095 |
| 13 | LivaNova PLC | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 14 | Conmed Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 15 | Orthofix Medical Inc. | 2025 | Massimo Calafiore | 848,322 | 4,499,988 | 1,500,009 | 445,579 | 7,310,039 |
| 16 | ZimVie Inc. | 2024 | Vafa Jamali | 818,461 | 6,367,343 | 0 | 0 | 7,209,869 |
| 17 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 18 | ICU Medical, Inc. | 2025 | Vivek Jain | 775,000 | 4,500,023 | 0 | 1,162,500 | 6,452,042 |
| 19 | Varex Imaging Corporation | 2025 | Sunny Sanyal | 815,816 | 2,662,978 | 0 | 1,131,894 | 4,634,688 |
| 20 | Globus Medical, Inc. | 2025 | Keith Pfeil | 479,467 | 0 | 2,982,347 | 783,000 | 4,400,159 |
| 21 | Bioventus Inc. | 2025 | Robert Claypoole | 824,110 | 1,982,530 | 662,949 | 781,256 | 4,299,108 |
| 22 | Paragon 28, Inc. | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 23 | Inogen, Inc. | 2025 | Kevin R.M. Smith | 711,077 | 1,874,550 | 0 | 0 | 2,613,804 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| ZimVie Inc. | 0% | RSU 100 | not disclosed | Aon |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| Bioventus Inc. | not disclosed | RSU 49 · PSU 26 · Options 25 | No | Aon plc |
| Conmed Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Embecta Corp. | 110.2% | not disclosed | No | Korn Ferry |
| Envista Holdings Corporation | 151% | PSU 60 · Options 20 · RSU 20 | No | Frederic W. Cook & Co, Inc. |
| Glaukos Corporation | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Globus Medical, Inc. | 102% | Options 100 | not disclosed | FW Cook |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| ICU Medical, Inc. | 150% | PSU 50 · RSU 50 | No | Compensia |
| Inogen, Inc. | 60% | RSU 50 · PRSU 50 | No | Aon |
| Integer Holdings Corporation | 85.75% | PSU 66 · RSU 34 | Yes — Relative TSR versus peer group | FW Cook |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| LivaNova PLC | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Merit Medical Systems, Inc. | 124.53% | PSU 60 · RSU 40 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| NuVasive, Inc. | 75% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Orthofix Medical Inc. | 47.7% | PSU 50 · Option 25 · RSU 25 | No | Meridian |
| Paragon 28, Inc. | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Varex Imaging Corporation | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-07 | 12,018,245 | 9,964,217 | 85,638 | 54.67% | Passed |
| 2024 | 2024-05-15 | 20,961,125 | 450,853 | 49,296 | 97.89% | Passed |
| 2023 | 2023-05-12 | 15,813,008 | 2,595,302 | 52,952 | 85.9% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-05-07 | 54.67%a |
| 2024 | 2024-05-15 | 97.89%b |
| 2023 | 2023-05-12 | 85.9%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 81 : 1 |
|---|---|
| CEO total compensation | $7,209,869 |
| Median employee compensation | $88,746 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David King | Director | 2025-03-31 | A | 3,710.58 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-03-31 | — | 1,163 | — | — | 1 insider, 1 accrual row | ||
| Vafa Jamali | Director | 2025-04-01 | A | 21,331 | 0 | 0 | Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-04-01 | D | 21,331 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-04-01 | D | 9,333 | 11 | 98,930 | Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-05-07 | — | 2,000 | — | — | 4 insiders, 4 accrual rows | ||
| Sally Crawford | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-05-15 | A | 48,379 | 0 | 0 | Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-05-15 | A | 16,127 | 0 | 0 | Common | Form 4 ↗ |
| Sandra Schneider | Chief Accounting Officer | 2025-05-15 | A | 11,127 | 0 | 0 | Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-05-15 | D | 8,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | Chief Accounting Officer | 2025-05-15 | D | 11,127 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | Chief Accounting Officer | 2025-05-15 | D | 2,710 | 9 | 23,658 | Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-05-15 | D | 16,127 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-05-15 | D | 3,927 | 9 | 34,283 | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-05-15 | D | 10,966 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-05-15 | D | 2,206 | 9 | 19,258 | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-05-15 | D | 2,671 | 9 | 23,318 | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-05-15 | A | 10,966 | 0 | 0 | Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-05-15 | A | 8,063 | 0 | 0 | Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-05-15 | D | 48,379 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-05-15 | D | 21,166 | 9 | 184,779 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-06-30 | — | 1,341 | — | — | 1 insider, 1 accrual row | ||
| Indraneel Kanaglekar | See remarks below. | 2025-07-01 | D | 145 | 10 | 1,393 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-09-30 | — | 662 | — | — | 1 insider, 1 accrual row | ||
| Richard Heppenstall | Exec. VP, CFO and Treasurer | 2025-10-01 | D | 1,057 | 19 | 20,009 | Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-10-20 | D | 149,190 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-10-20 | D | 40,127 | — | — | Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-10-20 | D | 6,755.86 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-10-20 | D | 83,674 | — | — | Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-10-20 | D | 13,072.97 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-10-20 | D | 786,541 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-10-20 | D | 389,152 | — | — | Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-10-20 | D | 227,851 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-10-20 | D | 125,389 | — | — | Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-10-20 | D | 8,289.99 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-10-20 | D | 6,755.86 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | See remarks below. | 2025-10-20 | D | 49,956 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | See remarks below. | 2025-10-20 | D | 40,794 | — | — | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-10-20 | D | 121,897 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-10-20 | D | 63,438 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 51 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David King | Director | 2025-03-31 | A | 3,710.58 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-03-31 | A | 1,163.03 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-04-01 | A | 21,331 | 0 | 0 | Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-04-01 | D | 21,331 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-04-01 | D | 9,333 | 11 | 98,930 | Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-05-07 | A | 500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-05-07 | A | 500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-05-07 | A | 500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-05-07 | A | 500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-05-07 | A | 21,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-05-15 | A | 48,379 | 0 | 0 | Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-05-15 | A | 16,127 | 0 | 0 | Common | Form 4 ↗ |
| Sandra Schneider | Chief Accounting Officer | 2025-05-15 | A | 11,127 | 0 | 0 | Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-05-15 | D | 8,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | Chief Accounting Officer | 2025-05-15 | D | 11,127 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | Chief Accounting Officer | 2025-05-15 | D | 2,710 | 9 | 23,658 | Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-05-15 | D | 16,127 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-05-15 | D | 3,927 | 9 | 34,283 | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-05-15 | D | 10,966 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-05-15 | D | 2,206 | 9 | 19,258 | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-05-15 | D | 2,671 | 9 | 23,318 | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-05-15 | A | 10,966 | 0 | 0 | Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-05-15 | A | 8,063 | 0 | 0 | Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-05-15 | D | 48,379 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-05-15 | D | 21,166 | 9 | 184,779 | Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-06-30 | A | 1,340.91 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-07-01 | D | 145 | 10 | 1,393 | Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-09-30 | A | 662.31 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Heppenstall | Exec. VP, CFO and Treasurer | 2025-10-01 | D | 1,057 | 19 | 20,009 | Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-10-20 | D | 149,190 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-10-20 | D | 40,127 | — | — | Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-10-20 | D | 6,755.86 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Heather Kidwell | See remarks below. | 2025-10-20 | D | 83,674 | — | — | Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-10-20 | D | 13,072.97 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-10-20 | D | 786,541 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vafa Jamali | Director | 2025-10-20 | D | 389,152 | — | — | Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-10-20 | D | 227,851 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Heppenstall | See remarks below. | 2025-10-20 | D | 125,389 | — | — | Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vinit Asar | Director | 2025-10-20 | D | 8,289.99 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sally Crawford | Director | 2025-10-20 | D | 6,755.86 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Richard Kuntz | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karen Matusinec | Director | 2025-10-20 | D | 57,728 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | See remarks below. | 2025-10-20 | D | 49,956 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sandra Schneider | See remarks below. | 2025-10-20 | D | 40,794 | — | — | Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-10-20 | D | 121,897 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Indraneel Kanaglekar | See remarks below. | 2025-10-20 | D | 63,438 | — | — | Common | Form 4 ↗ |
Sources (102 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Vafa Jamali. DEF 14A, filed 2025-03-25. Section “2024 Summary Compensation Table” · page 43. As printed: 7,209,869. View filing ↗
- Section 01, Richard Heppenstall. DEF 14A, filed 2025-03-25. Section “2024 Summary Compensation Table”. As printed: 2,339,103. View filing ↗
- Section 01, Heather Kidwell. DEF 14A, filed 2025-03-25. Section “2024 Summary Compensation Table”. As printed: 1,544,283. View filing ↗
- Section 01, Indraneel Kanaglekar. DEF 14A, filed 2025-03-25. Section “2024 Summary Compensation Table”. As printed: 1,380,548. View filing ↗
- Section 03, Richard Heppenstall RSU. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Vafa Jamali RSU. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Heather Kidwell RSU. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Richard Heppenstall Conversion. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Heather Kidwell Conversion. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Indraneel Kanaglekar Conversion. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Vafa Jamali Conversion. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Indraneel Kanaglekar RSU. DEF 14A, filed 2025-03-25. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A. Section “CEO Pay Ratio”. As printed: 81 : 1.
- Section 08, David King. DEF 14A, filed 2025-03-25. Section “Director Compensation”. As printed: 418,400. View filing ↗
- Section 08, Karen Matusinec. DEF 14A, filed 2025-03-25. Section “Director Compensation”. As printed: 288,400. View filing ↗
- Section 08, Richard Kuntz, M.D., M.Sc. DEF 14A, filed 2025-03-25. Section “Director Compensation”. As printed: 278,400. View filing ↗
- Section 08, Sally Crawford. DEF 14A, filed 2025-03-25. Section “Director Compensation”. As printed: 278,400. View filing ↗
- Section 08, Vinit Asar. DEF 14A, filed 2025-03-25. Section “Director Compensation”. As printed: 278,400. View filing ↗
- Section 08, Vafa Jamali. DEF 14A, filed 2025-03-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, David King 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-03-31. Form 4, filed 2025-04-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-04-01. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-04-01. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-04-01. Form 4, filed 2025-04-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vinit Asar 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Matusinec 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sally Crawford 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vinit Asar 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sally Crawford 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Matusinec 2025-05-07. Form 4, filed 2025-05-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Heppenstall 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Schneider 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heather Kidwell 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Schneider 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Schneider 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Heppenstall 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Heppenstall 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Indraneel Kanaglekar 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heather Kidwell 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Indraneel Kanaglekar 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Indraneel Kanaglekar 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heather Kidwell 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-05-15. Form 4, filed 2025-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-06-30. Form 4, filed 2025-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Indraneel Kanaglekar 2025-07-01. Form 4, filed 2025-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-09-30. Form 4, filed 2025-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Heppenstall 2025-10-01. Form 4, filed 2025-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heather Kidwell 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sally Crawford 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Matusinec 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heather Kidwell 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vafa Jamali 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Heppenstall 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Heppenstall 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vinit Asar 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vinit Asar 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sally Crawford 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sally Crawford 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Kuntz 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Matusinec 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Schneider 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Schneider 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Indraneel Kanaglekar 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Indraneel Kanaglekar 2025-10-20. Form 4, filed 2025-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-13. Item 5.07 · say-on-pay result. As reported: 54.67% (votes for as printed: 12,018,245). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-17. Item 5.07 · say-on-pay result. As reported: 97.89% (votes for as printed: 20,961,125). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-18. Item 5.07 · say-on-pay result. As reported: 85.9% (votes for as printed: 15,813,008). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 510,000 + equity 1,032,000 + all other 0 = 1,542,000, summed across the director compensation table rows.
- Merit Medical Systems, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Merit Medical Systems, Inc.'s own proxy. As printed: 13,755,143. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Glaukos Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. View filing ↗
- Nevro Corp., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. View filing ↗
- Envista Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Envista Holdings Corporation's own proxy. As printed: 10,559,567. View filing ↗
- Alphatec Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
- Avanos Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. View filing ↗
- Embecta Corp., Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Embecta Corp.'s own proxy. As printed: 9,400,088. View filing ↗
- Integra LifeSciences Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. View filing ↗
- AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- Integer Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integer Holdings Corporation's own proxy. As printed: 8,671,332. View filing ↗
- NuVasive, Inc., Section 10b CEO total. DEF 14A, filed 2023-05-08. CEO total compensation as printed in NuVasive, Inc.'s own proxy. As printed: 8,077,095. View filing ↗
- LivaNova PLC, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova PLC's own proxy. As printed: 8,047,217. View filing ↗
- Conmed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Conmed Corporation's own proxy. As printed: 7,634,873. View filing ↗
- Orthofix Medical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Orthofix Medical Inc.'s own proxy. As printed: 7,310,039. View filing ↗
- ZimVie Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-03-25. CEO total compensation as printed in ZimVie Inc.'s own proxy. As printed: 7,209,869. View filing ↗
- Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
- ICU Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in ICU Medical, Inc.'s own proxy. As printed: 6,452,042. View filing ↗
- Varex Imaging Corporation, Section 10b CEO total. DEF 14A, filed 2025-12-29. CEO total compensation as printed in Varex Imaging Corporation's own proxy. As printed: 4,634,688. View filing ↗
- Globus Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Globus Medical, Inc.'s own proxy. As printed: 4,400,159. View filing ↗
- Bioventus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bioventus Inc.'s own proxy. As printed: 4,299,108. View filing ↗
- Paragon 28, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-05. CEO total compensation as printed in Paragon 28, Inc.'s own proxy. As printed: 3,232,420. View filing ↗
- Inogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. View filing ↗
- Section 10a, Orthofix Medical Inc. reciprocity. DEF 14A. Orthofix Medical Inc. names ZimVie Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Inogen, Inc. reciprocity. DEF 14A. Inogen, Inc. names ZimVie Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Varex Imaging Corporation reciprocity. DEF 14A. Varex Imaging Corporation names ZimVie Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗